Athanor Capital, LP Tg Therapeutics, Inc. Transaction History

Athanor Capital, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$32.5 - $48.96 $1.94 Million - $2.92 Million	-59,620 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$41.61 - $54.3 $1.31 Million - $1.7 Million	-31,387 Reduced 34.49%	59,620 $2.87 Million
Q4 2020 Feb 16, 2021	BUY	$25.27 - $54.9 $622,880 - $1.35 Million	24,649 Added 37.15%	91,007 $4.73 Million
Q3 2020 Nov 16, 2020	SELL	$18.49 - $27.24 $865,720 - $1.28 Million	-46,821 Reduced 41.37%	66,358 $1.78 Million
Q2 2020 Aug 13, 2020	BUY	$8.9 - $21.84 $1.01 Million - $2.47 Million	113,179 New	113,179 $2.21 Million
Q1 2020 May 14, 2020	SELL	$7.14 - $15.99 $236,334 - $529,269	-33,100 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$5.1 - $11.2 $168,810 - $370,720	33,100 New	33,100 $367,000
Q3 2019 Nov 14, 2019	SELL	$5.38 - $8.99 $123,202 - $205,871	-22,900 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$6.27 - $8.65 $143,583 - $198,085	22,900 New	22,900 $198,000

340

88.5M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $5.09B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Athanor Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Athanor Capital, LP with notifications on news.